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ABSTRACT 
Christina L. Lebonville: Acquisition of Heroin Conditioned Immunosuppression Requires 
Il-1 Signaling in the Dorsal Hippocampus 
(Under the direction of Donald T. Lysle) 
 
Opioid users experience increased infection rates. While partially attributable to direct 
opiate-immune interactions, conditioned immune responses contribute as well. Neural circuitry 
governing opioid conditioned immune responses has been investigated, but mediating 
mechanisms are unknown. Previous studies showed that hippocampal IL-1 signaling is required 
for expression of heroin conditioned immunosuppression following learning. Current studies 
were designed to further characterize hippocampal IL-1’s role in this phenomenon by 
manipulating IL-1 during learning. Experiment 1 tested whether hippocampal IL-1 is required 
for the acquisition of heroin conditioned immunosuppression. Experiment 2 tested whether 
hippocampal IL-1 is required for unconditioned heroin immunosuppression. Blocking IL-1 
signaling in the dorsal hippocampus with IL-1RA during each conditioning session, but not on 
interspersed non-conditioning days, attenuated the acquisition of heroin conditioned 
immunosuppression. IL-1RA treatment did not alter unconditioned immunosuppression to a 
single dose of heroin. Thus, IL-1 signaling may play a role in learning the association between 
heroin and context.  
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CHAPTER 1: ACQUISITION OF HEROIN CONDITIONED IMMUNOSUPPRESSION 
REQUIRES IL-1 SIGNALING IN THE DORSAL HIPPOCAMPUS 1 
 
Introduction 
Opioid users show an increased incidence of infections (Govitrapong et al., 1998; Louria 
et al., 1967; Risdahl et al., 1998), the treatment of which imposes a large economic burden (Mark 
et al., 2001). These infections are not simply due to increased pathogen exposure from 
intravenous drug use, but may also be attributed to opiates’ interaction with the immune system 
(Horsburgh et al., 1989; Simonovska et al., 2011; Vallejo et al., 2004). Furthermore, while 
opioids on their own hinder the body’s ability to respond to disease and infection, these 
immunosuppressive properties can become conditioned. Repeated presentations of immune 
modulators, like opioids, with predictive stimuli can result in Pavlovian conditioning of immune 
system function, allowing for these stimuli to later affect the immune system in the same way as 
the modulators themselves [for review (Schedlowski and Pacheco-Lopez, 2010)]. Therefore, 
exposure to opioid-associated environments or stimuli might then lead to an exacerbation of 
immunological vulnerability in opioid users. 
Conditioned immune responses have been demonstrated in rodent models using stimuli 
paired with distinct immunosuppressive agents such as cyclophosphamide (Ader, 1974; Ader and 
Cohen, 1975), cyclosporine A (Exton et al., 2001; Exton et al., 1998a; Exton et al., 1998b; von 
Horsten et al., 1998), foot shock stress (Lysle et al., 1988; Perez and Lysle, 1995), cocaine 
1This chapter previously appeared as an article in the journal Brain, Behavior, and Immunity. The original citation is 
as follows: Lebonville, C.L. et. al. 2016. Acquisition of Heroin Conditioned Immunosuppression Requires IL-1 
Signaling in the Dorsal Hippocampus. Brain, Behav., and Imm. In Press.  
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(Kubera et al., 2008), morphine (Coussons-Read et al., 1994a, b; Coussons et al., 1992; Luecken 
and Lysle, 1992), and heroin (Lysle and Ijames, 2002; Szczytkowski et al., 2011; Szczytkowski 
and Lysle, 2007, 2008, 2010).  
Heroin conditioned immune effects are of particular concern due to recent rises in 
heroin’s use (United States. Substance Abuse and Mental Health Services Administration, 2014). 
The NIH attributes this rise to the near tripling of opioid prescriptions in order to treat pain in the 
last decade that may have led many to turn to heroin as a cheaper alternative to costly pain 
medication (United States. National Institute on Drug Abuse, 2014). With opioid use, including 
heroin, on the rise, it becomes more important than ever to understand the immune consequences 
of their use and the neural mechanisms governing the classical conditioning that may increase 
the severity or duration of these consequences. 
Like other forms of immune conditioning, which have been primarily studied within the 
context of placebo effects [for review (Schedlowski et al., 2015)], opioid immune conditioning is 
centrally mediated (Fecho et al., 1996; Lysle et al., 1996) and depends on learned associations 
between a conditioned stimulus (CS) and opioids, as unconditioned stimuli (US). After multiple 
pairings of the CS and the US, the CS itself becomes able to evoke a conditioned response (CR) 
similar to the effects of opioids themselves (Lysle and Ijames, 2002). For example, a single 
injection of heroin has been shown to suppress measures of nitric oxide (NO) (Lysle and How, 
2000), an important part of the immune system released by multiple immune cells that conveys 
resistance to infection and serves as a regulator of immune function (Bogdan, 2001; Lewis et al., 
2010; MacMicking et al., 1995; Nathan and Shiloh, 2000; Uehara et al., 2015).  Its expression is 
potently and widely induced by lipopolysaccharide (LPS), a component of gram negative 
bacterial walls. NO production can be indirectly measured by levels of inducible nitric oxide 
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(iNOS), the enzyme responsible for producing NO, and nitrate/nitrite, byproducts of NO 
degradation in the blood. 
Previous studies have taken advantage of LPS’s potent induction of NO to investigate 
heroin’s immune effects (Lysle and How, 2000). The effects of heroin on LPS-induced NO are 
also able to be conditioned to heroin-associated stimuli. Pairing heroin (US) with a distinct 
environmental context (CS) allows the heroin-paired context to evoke a CR in rats in that the 
exposure to the context alone will cause conditioned suppression of NO (Lysle and Ijames, 2002; 
Szczytkowski et al., 2011; Szczytkowski et al., 2013; Szczytkowski and Lysle, 2007, 2008, 
2010). Research using this model has demonstrated that the basolateral amygdala, nucleus 
accumbens (Saurer et al., 2009; Szczytkowski and Lysle, 2008), and a circuit comprised of these 
regions and the ventral tegmental area is necessary for the expression of heroin conditioned 
immunosuppression (Szczytkowski et al., 2011). More recently, the hippocampus, a brain region 
heavily implicated in contextual learning (Maren and Holt, 1999; Phillips and Ledoux, 1994; 
Redish, 2001) has also been shown to be involved in the expression of heroin conditioned 
immunosuppression. Inactivation of the dorsal hippocampus (DH) using a GABA agonist 
cocktail, baclofen/muscimol, or knockdown of interleukin-1β (IL-1β) signaling within the DH 
just before testing prevented a heroin-paired context from suppressing the immune response to 
LPS (Szczytkowski et al., 2013). This not only suggests the requirement of the DH for the 
expression of heroin conditioned immunosuppression, but also implicates a novel role for brain 
IL-1β in this effect. 
IL-1β is a pro-inflammatory cytokine that has been linked to learning and memory. 
Studies suggest this cytokine is induced in the DH by Pavlovian conditioning (Goshen et al., 
2007), is required for the maintenance of long-term potentiation (LTP) (Schneider et al., 1998), 
and causes disruption of normal memory at either supra- or sub-optimal expression levels (Avital 
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et al., 2003; Ben Menachem-Zidon et al., 2011; Goshen et al., 2007; Griffin et al., 1989; Ross et 
al., 2003; Schmid et al., 2009; Schneider et al., 1998). Furthermore, IL-1 seems to play a key role 
in memory within the hippocampus as IL-1 manipulations specifically affect hippocampal-
dependent memory but not hippocampal-independent memory [for review (Lynch, 2015)], and 
levels of IL-1 receptor in the hippocampus are particularly high [see (Schneider et al., 1998)].  
Given that IL-1 in the hippocampus is important for the expression of heroin conditioned 
immunosuppression, it is yet to be determined if hippocampal IL-1 is also required for the 
encoding of immune associations during acquisition. Therefore, in the present studies, 
Experiment 1 sought to investigate whether hippocampal blockade of the most well-studied 
receptor for IL-1, IL-1 receptor 1 (IL-1R1), could interfere with the acquisition of heroin 
conditioned immunosuppression.  
Many studies suggest that the CR is specific to and mimics the effects of the US [see 
(Schedlowski et al., 2015)], which may suggest that the neural pathways engaged during the 
expression of a CR recapitulate those engaged by the US. In the context of our model, it is 
unknown whether IL-1 signaling is required for heroin’s immunosuppressive effects. If IL-1 in 
the dorsal hippocampus is specifically required for memory processes engaged in connecting the 
immune effects of the US to the CS, then blockade of IL-1 signaling in the dorsal hippocampus 
will not interfere with the immunosuppressive response to a heroin US. Experiment 2 
investigated the possibility that IL-1 in the dorsal hippocampus has a distinguishable role in 
associative learning and not in mediating the unconditioned response to the US.  
The present studies will critically inform our understanding of how stimuli-drug 
associations engage memory and immune systems, possibly providing therapeutic targets to aid 
in the prevention of the negative health consequences associated with opioid use.  
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Methods and Materials 
General Methods 
Animals. Adult, male Lewis rats (N = 55) weighing 225-250 g were purchased from 
Charles-River Laboratories (Raleigh, NC). Animals were housed individually in a colony room 
under a reversed 12-hour day-night cycle, with ad libitum access to food and water. Animals 
received at least 12 days of habituation before experimentation and were handled regularly 
during this time. All procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of North Carolina at Chapel Hill and conformed to the 
National Research Council’s Guide for the Care and Use of Laboratory Animals (Institute for 
Laboratory Animal Research Division of Earth and Life Studies). 
Drugs & Delivery. Heroin (diacetylmorphine) was obtained from NIDA’s Drug Supply 
System (Bethesda, MD) and was dissolved in 0.9 % sterile saline to a final concentration of 1.0 
mg/mL. Throughout conditioning, heroin solutions were stored at 4°C. Heroin-filled syringes 
were allowed to come to room temperature prior to injections. Rats were injected subcutaneously 
with 1.0 mg/kg heroin, a dose chosen based on prior experiments in our laboratory showing that 
this dosage alters LPS-induced iNOS mRNA expression in the spleen (Lysle and How, 2000, 
Lysle and Ijames, 2002, Szczytkowski and Lysle, 2007). Lipopolysaccharide (LPS) was injected 
subcutaneously at a concentration of 1 mg/kg (derived from E. coli, serotype 055:B5, dissolved 
in sterile, pyrogen-free saline), a dose which induces sickness behavior and produces reliable 
induction of nitric oxide measures. This particular serotype has been used previously in our 
laboratory to investigate immune responses following heroin conditioning, an important 
verification due to the differing activity between LPS serotypes even from within the same 
species (Caroff et al., 2002). Human recombinant interleukin-1 receptor antagonist (IL-1RA) 
(Genscript, Piscataway, NJ, Catalog No: Z00367) was reconstituted in 0.9% sterile saline to a 
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final concentration of 2.5 μg/μL. Reconstituted IL-1RA was then aliquoted and stored at -20°C. 
Rats were intracranially infused with 1.25 μg in 0.5 μL volume per hemisphere into the dorsal 
hippocampus (DH) over 2 minutes at a constant rate of 0.25 μL/min. Thereafter, the injectors 
were allowed to sit for 1 additional minute to allow for proper diffusion from the injection site. 
At least 48 hours prior to intracranial drug infusion into the DH, injectors were lowered into the 
cannulae and the rats were handled to habituate them to the infusion procedures. Just prior to 
infusion, frozen IL-1RA aliquots were thawed on ice, briefly centrifuged, and stored on ice 
throughout. Vehicle infusions were of 0.9% sterile saline.   
Surgical Procedure. Animals were anesthetized with 1.0 mL/kg intraperitoneally 
injected 9:1 (vol:vol) ketamine hydrochloride (100 mg/mL) and xylazine (100 mg/mL). 
Surgically prepared animals were placed into the stereotaxic apparatus where guide cannula (26-
gauge, Plastics One, Roanoke, VA) were directed bilaterally toward the DH with coordinates AP 
-3.4 mm, ML ±3.1 mm, DV -2.2 mm, relative to bregma; 15o angle laterally (Paxinos and 
Watson, 1998).  Animals were given at least 13 days for post-operative recovery during which 
they were handled and monitored regularly.   
Conditioning Procedure. Rats received five, 60-min conditioning sessions every other 
day as in prior studies, which has been shown to be sufficient to generate conditioned 
immunosuppression to the heroin-paired context (Szczytkowski et al., 2011; Szczytkowski et al., 
2013; Szczytkowski and Lysle, 2010). Each conditioning session involved heroin administration 
(US) immediately followed by placement into a conditioning chamber (BRS/LVE, Laurel, MD, 
USA; W 30.5 cm x D 24.1 cm x H 26.7 cm) that served as the conditioned stimulus (CS). The 
conditioning chambers were contained within closable sound and light attenuating chambers (W 
50.8 cm x D 34.3 cm x H 36.8 cm) with house fans, located in a room separate from the animal 
colony. The conditioning chambers contained a standard footshock metal bar floor, two clear 
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plastic front and black walls, a clear plastic ceiling, and two metal side walls. Below the bar 
floor, a floor tray containing cedar bedding was inserted to enhance the distinction of the 
conditioning environment from the home cage. In between animals, chambers were thoroughly 
cleaned using Roccal-D Plus disinfectant (Zoetis, Kalamazoo, MI).  
Prior work in our laboratory has shown that unmanipulated animals, saline conditioned 
animals, or animals that received the CS and US in an unpaired manner do not demonstrate 
context-induced immunosuppression. This indicates that immunosuppression is specifically due 
to re-exposure to a heroin-paired CS and not ancillary effects of conditioning, receiving heroin, 
or injections in general (Lysle and Ijames, 2002).   
Tissue Collection. Immediately after the 60-min test session (or home cage exposure for 
controls), rats were injected with LPS. Rats were sacrificed and tissue was collected 6 hours after 
LPS injection. The spleen was analyzed because immunohistochemical localization of iNOS in 
rats exposed to LPS shows the presence of the iNOS enzyme in a number of immune cells found 
in the spleen, including macrophages, lymphocytes, and neutrophils (Bandaletova et al., 1993). 
Following sacrifice, spleen was dissected out and cut into approximately 100 mg sized pieces for 
RT-qPCR and ELISA. Tissue was placed in cOmplete Protease Inhibitor Cocktail (Roche 
Diagnostics, Indianapolis, IN) and stored at -80°C. 
RNA Extraction & RT-qPCR. To determine iNOS mRNA expression, reverse 
transcription quantitative real-time PCR (RT-qPCR) was performed on spleen tissue samples. 
Collected tissue was processed by the UNC Animal Clinical Chemistry and Gene Expression 
Laboratories according to previous protocols (Kim et al., 2002). Briefly, tissue was homogenized 
in RNA lysis buffer (PE Biosystems, Foster City, CA) with Ca2+ and Mg2- free PB using a Fast 
Prep 120 mixer (QBIOgene, Vista, CA). RNA was purified using an automated nucleic-acid 
workstation (ABI Prism 6700, PE Biosystems) according to the manufacturer’s protocol. The 
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amount of RNA used in the RT-qPCR reaction (one-step) was equalized between samples. RT-
qPCR reactions were performed in a sequence detector (ABI Prism 7700, PE Biosystems) in a 
total volume of 30 μL (10 μL RNA, 20 μL reaction cocktail). Each RT-qPCR amplification was 
performed in duplicate under the following reaction conditions: 30 min at 48°C for the RT 
reaction, 10 min at 94°C, and then 40 cycles of 15s at 94°C and 1 min at 60°C. Raw results were 
normalized to reference gene 18S to control for small variations in the amount of starting cDNA 
template. The stability of 18S as a reference gene was verified using a 2x2 ANOVA to 
demonstrate that there were no significant group differences in 18S expression. Normalized 
values were then calibrated against either a global normalized average Ct value (Experiment 1) 
or a control group normalized average Ct (Experiment 2) for the gene of interest. For graphical 
representation, delta delta Ct values were linearly transformed. The nucleotide sequences of the 
qPCR primers and fluorogenic probes used for iNOS and 18S were as follows - iNOS forward: 
5’-AGCGGCTCCATGACTCTCA-3’, reverse: 5’-TGCCTGCACCCAAACACCAA-3’, probe: 
5’-FTCATGCGGCCTCCTTTGAGCCCTCQ-3’; 18S forward: 5’-
AGAAACGGCTACCACATCCA-3’, reverse: 5’-CTCGAAAGAGTCCTGTATTGT-3’, probe: 
5’-FAGGCAGCAGGCGCGCAAATTACQ-3’ [F = 5’- Fluorescein (FAM); Q = Quencher 
(TAMRA)]. 
Protein Extraction/Quantification & iNOS ELISA. Spleen tissue was homogenized on 
ice in sterile Dounce grinders. Protein was extracted from homogenized samples using cycles of 
freeze-thaw lysis, centrifugation, and collection of the supernatant. Total protein was quantified 
by Bradford Assay. Briefly, 10 μL of 1:200 diluted protein, in triplicate, was incubated with 200 
μL diluted and filtered Bradford Assay Dye (Bio-Rad Laboratories Inc., Hercules, CA, Catalog 
No. 500-0006) for 10 min. The absorbance of each sample triplicate was measured in a 
spectrophotometer (EpochTM, BioTek Instruments Inc., Winooski, VT) at 595 nm, averaged, and 
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compared to a concurrently run BSA standard curve to determine μg/μL concentration. Splenic 
iNOS protein was quantified using a rat iNOS sandwich ELISA kit (LifeSpan BioSciences, Inc., 
Seattle, WA, Catalog No. LS-F4109). The user manual supplied with the kit was followed with 
the following parameters: 200 µg of total protein per sample was loaded in duplicate, plates were 
gently agitated at 45-55 rpm, and color was allowed to develop for 20-25 min. The ELISA plate 
was washed with an automatic plate washer (EL 403, BioTek Instruments Inc., Winooski, VT) as 
recommended by the kit manual. Each plate was read in a spectrophotometer at 450 nm and 
compared to a concurrently run standard curve to determine pg iNOS protein per 200 µg of total 
protein. 
Nitrate/Nitrite Assay. The nitrate/nitrite concentration in plasma samples was assessed 
using the Greiss reagent assay as described previously (Szczytkowski and Lysle, 2007). Briefly, 
12 μL of plasma diluted in 38 μL of dH2O was incubated in the dark for 90 min with 10 μL of 
nitrate reductase (1.0 U/mL), 20 μL of 0.31 M phosphate buffer (pH 7.5), 10 μL of 0.86 mM 
beta-nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt (NADPH, Sigma-
Aldrich Inc., Milwaukee, WI), and 10 μL of 0.11 mM flavin adenine dinucleotide in individual 
wells of a 96-well plate. Then, 200 mL of Greiss reagent, consisting of a 1:1 (v/v) solution 1% 
sulfanilamide in 5.0% phosphoric acid and 0.1% N-(1-Naphthyl)ethylenediamine 
dihydrochloride (Kodak) in distilled water, was added to the samples. The color developed for 10 
min at room temperature, after which, absorbance at 550 nm was determined using a 
spectrophotometer. All reactions were carried out in triplicate. The total micromolar 
concentration of nitrite was determined for each sample based on a concurrently produced 
standard curve. Recovery of nitrate is greater than 95% using this assay. 
 Histology. To confirm proper cannula placement, Alcian blue dye was infused via the 
cannulae following euthanasia. For Experiment 1, brains were extracted and immediately flash 
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frozen in a low temperature freezing bath (Histobath NesLab, Portsmouth, NH; Shandon 
Lipshaw, Pittsburgh, PA) with freezing-cold isopentane, wrapped in aluminum foil, and stored at 
-80°C. For Experiment 2, brains were extracted and post-fixed at 4°C for 5 days in 4% 
paraformaldehyde. Following fixation, the brains were transferred to 30% sucrose solution for 
three days for cryoprotection. Brains were then frozen in a low temperature freezing bath 
(Histobath NesLab, Portsmouth, NH; Shandon Lipshaw, Pittsburgh, PA) with freezing-cold 
isopentane, wrapped in aluminum foil, and stored at -80°C. For both experiments, 40 μm coronal 
sections were collected using a freezing microtome (Leica CM 3050 S, Leica-Microsystems, 
Germany) and allowed to dry on the slide for 30 min at room temperature before analysis. 
Cannula tracts were identified under a light microscope and the most ventral point of each tract 
was documented on rat brain atlas figures. Subjects with incorrect placement of cannula were 
removed from all analyses. Sections were stained with thionin and coverslipped for long-term 
storage.  
Statistical Analysis. A 2x2 analysis of variance (ANOVA) was performed on data sets 
using SPSS Statistics (IBM, Armonk, NY), after verifying that the underlying assumptions of the 
test were met. Homogeneity of variance was tested using Levene’s Test and normality using 
Shapiro-Wilk Test. For all tests, the significance level was set at 0.05. Tukey’s Honestly 
Significant Difference (HSD) post-hoc test was then used to detect either differences between 
CS-exposed and corresponding home cage control groups (Experiment 1) or differences between 
heroin-injected vs. saline-injected groups and the effect of pre-treatment with IL-1RA vs. saline 
within heroin-injected groups (Experiment 2). For RT-qPCR, statistics were run on delta delta Ct 
values and not the linear transform because the former demonstrated normality. 
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Figure 1. Experimental Design of Experiment 1.Following a surgery recovery period, rats were conditioned to 
associate a heroin injection with a distinct context. Rats in one group received an infusion of IL-1 receptor 
antagonist (IL-1RA) into the dorsal hippocampus (DH) 30 min before each of the five conditioning sessions 
(IL-1RA With Cond). Rats in another group received an IL-1RA infusion into the DH 24 h after the previous 
conditioning session, on non-conditioning days (IL-1RA 24 h After Cond). Number of injections and injection 
manipulations were balanced between each group using saline infusions. Six days after the last infusion, half of 
the animals from each group were either re-exposed to the heroin-paired context (CS) to test for conditioned 
immunosuppression or remained in the home-cage for an equivalent period of time (HC). Immediately 
following, all animals were given a single injection of LPS and were sacrificed 6 hours later. 
 
Experiment Specific Procedures 
Experiment 1: IL-1RA Antagonism During Acquisition of Heroin Conditioned 
Immunosuppression. For Experiment 1, animals (N = 31) were repeatedly microinjected with 
IL-1RA into the DH at two time points relative to conditioning. One group (IL-1RA With Cond; 
n = 16) received IL-1RA 30 minutes prior to receiving heroin and being placed into the 
conditioning chamber to test whether DH IL-1 signaling during conditioning is required for 
acquisition of heroin conditioned immunosuppression. Another group (IL-1RA 24 h After Cond; 
n = 15) received IL-1RA 24 hours after conditioning, on the days in between conditioning 
sessions (non-conditioning days), to test whether IL-1 signaling is specifically required during 
conditioning sessions for acquisition. For both groups, infusions were given on both conditioning 
and non-conditioning days and vehicle infusions were given at times when animals were not 
administered IL-1RA (Figure 1). This design ensured that all animals received injections before 
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conditioning and that all animals received the same total number of IL-1RA infusions. This 
meant that differences between groups would not reflect ancillary effects of infusion timing 
relative to conditioning nor possible non-specific compensatory effects from receiving multiple 
IL-1RA injections. IL-1RA has a short half-life when injected systemically (21-108 minutes) 
(Granowitz et al., 1992). Unfortunately there is no data confirming the timeline of IL-1RA 
clearance from brain tissue. However, studies investigating effects of intracerebroventricular or 
hippocampal infusion of IL-1RA have shown that IL-1RA effects may last on the order of hours 
(Schmid et al., 2009; Schneider et al., 1998). This evidence suggests that separating IL-1RA 
treatment regimens by a full day, as in the current study, will likely limit temporal overlap of IL-
1RA action between groups.  
Six days after the last infusion (seven from the last conditioning session), half of the rats 
from each group were tested for expression of conditioned immunosuppression by being re-
exposed to the conditioning chamber (CS) for a single 60-min session, while the other half were 
not re-exposed and instead remained in their home cages (HC) for 60 min. Thus, conditioning in 
the latter group of home-cage controls was not evoked and this group was used for baseline 
comparison within each treatment regimen. Immediately thereafter, all rats received a single 
subcutaneous injection of LPS to induce in vivo production of nitric oxide. Rats were sacrificed 6 
hours after LPS injection by cervical dislocation and a sample of spleen and blood were obtained 
for the analysis of iNOS mRNA, iNOS protein, and nitrate/nitrite.  
Experiment 2: IL-1RA Antagonism During Heroin Unconditioned 
Immunosuppression. For Experiment 2, animals (N = 24) received a DH infusion of either IL-
1RA or vehicle 30 min before a single subcutaneous heroin or saline injection (Figure 2). In 
order to mirror the time point of Experiment 1, animals were returned to their home cage for an 
hour, the length of Experiment 1 conditioning sessions, and were then injected a single time 
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Figure 2. Experimental Design of Experiment 2. Following a surgery recovery period, rats received an 
infusion of IL-1 receptor antagonist (IL-1RA) or saline (Sal) into the dorsal hippocampus (DH) 30 min 
before a single subcutaneous injection of saline (Sal) or heroin (Her). One hour later, all animals were 
given a single injection of LPS and were sacrificed 6 hours later. 
subcutaneously with LPS to induce in vivo production of nitric oxide. Six hours after LPS 
injection, rats were sacrificed by cervical dislocation and a sample of spleen and blood were 
obtained for the analysis of iNOS mRNA, iNOS protein, and nitrate/nitrite.  
 
 
 
Results 
Experiment 1 investigated the effects of DH IL-1 signaling blockade on the acquisition of 
heroin conditioned immunosuppression by injecting IL-1RA into the DH either during each 
conditioning session or 24 hours after each conditioning session, on non-conditioning days. In 
the final analyses, group sizes were n = 8 for IL-1RA With Cond - HC, IL-1RA With Cond - CS, 
and IL-1RA 24 h After Cond - CS groups. For the IL-1RA 24 h After Cond - HC group, n = 7 
for nitrate/nitrate and iNOS protein analyses and n = 6 for iNOS mRNA analyses. One subject 
was removed from iNOS mRNA analysis due to outlying housekeeping data that signified a 
problem with RNA extraction/cDNA synthesis. 
A 2x2 ANOVA revealed significant differences between groups for splenic iNOS mRNA 
(F(3,26) = 13.857, p < 0.001, Figure 3A). There were significant main effects of drug timing 
(F(1,26) = 11.387, p < 0.01) and exposure treatment (F(1,26) = 23.836, p < 0.001) on iNOS mRNA. 
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Figure 3. Immune suppression to CS is attenuated by IL-1 signaling blockade before conditioning with 
heroin. IL-1 receptor antagonist (IL-1RA) administered just before each context-heroin pairing (left two 
bars), but not 24 h after on non-conditioning days (right two bars), attenuated suppression of splenic iNOS 
mRNA (A), splenic iNOS protein (B), and plasma nitrate/nitrite (C) upon re-exposure to the context (CS, 
light grey) compared to respective home cage controls receiving the same timing of IL-1RA treatment 
where conditioning was not evoked (HC, dark grey). Conditioned immune suppression to the CS was seen 
only in groups that received IL-1RA on non-conditioning days. (*, significantly different relative to 
respective control group; Tukey’s HSD, p < 0.05).   
Post-hoc analysis, using Tukey’s HSD, revealed that iNOS mRNA was statistically significantly 
reduced in animals that were re-exposed to the CS and received IL-1RA 24 h after conditioning 
(IL-1RA 24 h After Cond – CS), compared to the corresponding home cage control group that 
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was not re-exposed but received the same treatment regimen (IL-1RA 24 h After Cond – HC, p < 
0.001). No statistically significant suppression of iNOS mRNA was seen in animals re-exposed 
to the CS that received IL-1RA treatment just before each conditioning session (IL-1RA With 
Cond – CS), compared to the corresponding home cage control group that was not re-exposed 
(IL-1RA With Cond – HC, p > 0.17), indicating that DH IL-1RA blocked the acquisition of 
heroin conditioned suppression of iNOS mRNA when administered just before, but not 24 h 
after, conditioning sessions.  
A 2x2 ANOVA revealed significant differences between groups for splenic iNOS protein 
as well (F(3,27) = 6.073, p < 0.01, Figure 3B). There were significant main effects of drug timing 
(F(1,27) = 5.244, p < 0.04) and exposure treatment (F(1,27) = 8.83, p < 0.01) on iNOS protein. Post-
hoc analysis, using Tukey’s HSD, revealed that, like with iNOS mRNA, iNOS protein was 
statistically significantly reduced in animals that received DH IL-1RA 24 h after conditioning, on 
non-conditioning days, and were re-exposed to the CS (IL-1RA 24 h After Cond – CS) compared 
to the corresponding home cage control group that was not re-exposed but received the same 
treatment regimen (IL-1RA 24 h After Cond – HC, p < 0.02). No statistically significant 
suppression of iNOS protein was seen in animals that received IL-1RA treatment just before 
each conditioning session (IL-1RA With Cond – CS) compared to the corresponding home cage 
control group that was not re-exposed (IL-1RA With Cond – HC, p > 0.87). These results 
demonstrate that IL-1RA administration into the DH during conditioning, but not 24 h later, 
disrupts the acquisition of heroin conditioned suppression of iNOS protein.  
A 2x2 ANOVA revealed significant differences between groups for plasma nitrate/nitrite 
as well (F(3,27) = 7.518, p < 0.01, Figure 3C). There were significant main effects of drug timing 
(F(1,27) = 6.810, p < 0.02) and exposure treatment (F(1,27) = 14.387, p < 0.01) on plasma 
nitrate/nitrite. Post-hoc analysis, using Tukey’s HSD, revealed that nitrate/nitrite was statistically 
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significantly reduced in animals that received IL-1RA 24 h later on non-conditioning days when 
re-exposed to the CS (IL-1RA 24 h After Cond - CS) in comparison to the corresponding home 
cage control group that was not re-exposed (IL-1RA 24 h After Cond - HC, p < 0.02). No 
statistically significant suppression of nitrate/nitrite upon re-exposure to the CS was seen in 
animals that received IL-1RA treatment just before each conditioning session (IL-1RA With 
Cond - CS) compared to the corresponding home cage control group that was not re-exposed 
(IL-1RA With Cond - HC, p > 0.17).  
Thus, we observed significant attenuation of heroin conditioned immunosuppression 
when IL-1RA was infused into the DH just before, but not 24 h after, each conditioning session 
in both iNOS mRNA and protein and in plasma nitrate/nitrite. This indicates that IL-1 signaling 
blockade in the DH during conditioning sessions blocks acquisition of heroin conditioned 
immunosuppression. 
Experiment 2 investigated the effects of DH IL-1 signaling blockade on heroin 
unconditioned immunosuppression. In the final analyses, group sizes were n = 6 for the Sal/Sal 
group, n = 7 for Sal/Her and IL-1RA/Sal groups, and n = 4 for the IL-1RA/Sal group. Three 
subjects were removed from analysis due to incorrect cannula placement. 
A 2x2 ANOVA revealed a significant difference between treatment groups (iNOS 
mRNA: F(3,20) = 9.604, p < 0.001, Figure 4A; iNOS protein: F(3,20) = 16.007, p < 0.001, Figure 
4B; nitrate/nitrite: F(3,20) = 13.934, p < 0.001, Figure 4C). There was a significant main effect of 
heroin treatment for iNOS mRNA (F(1,20) = 26.050, p < 0.001), iNOS protein (F(1,20) = 46.741, p 
< 0.001), and plasma nitrate/nitrite (F(1,20) = 40.728, p < 0.001). There was no main effect of IL-
1RA treatment for iNOS mRNA, iNOS protein, or nitrate/nitrite (p > 0.4 for all measures). Post-
hoc analysis, using Tukey’s HSD, revealed that heroin-injected groups showed significantly 
decreased immune activation compared to saline-injected control groups (iNOS mRNA: p < 
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Figure 4. Immune suppression to heroin is not attenuated by IL-1 signaling blockade. IL-1 receptor 
antagonist (IL-1RA) administered 30 min before (light grey bars) an injection of heroin did not attenuate 
suppression of splenic iNOS mRNA (A), splenic iNOS protein (B) and plasma nitrate/nitrite (C). (*, 
significantly different; Tukey’s HSD, p < 0.05).   
 
0.05; iNOS protein: p < 0.006; nitrate/nitrite: p < 0.01), but there was no effect of IL-1RA 
treatment on heroin suppression of these measures to immune challenge (iNOS mRNA: p > 0.38;  
iNOS protein: p > 0.68; nitrate/nitrite: p > 0.74). This indicates that IL-1RA in the DH does not 
block unconditioned immunosuppression by a single heroin injection. It is possible, however, 
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that over repeated treatments of heroin and IL-1RA, as in the dosing regimen used in Experiment 
1, that effects of IL-1RA on heroin immunosuppression would begin to arise.  
Discussion  
 Heroin-paired contexts gain the ability to suppress the immune system, like heroin itself, 
through conditioning. This effect could contribute to the increased risk of infection seen in 
heroin users. Evidence suggests that the cytokine interleukin-1β (IL-1β) is required at 
physiological levels to support learning and memory. We demonstrate here that preventing IL-1 
signaling centrally in the dorsal hippocampus (DH) during each conditioning session in the 
acquisition phase, a time when heroin and a context can become associated, prevents the heroin-
paired context from suppressing the immune system during a subsequent expression test. This 
effect was not seen if IL-1 signaling was blocked in the DH between conditioning sessions on 
non-conditioning days. Subsequently, we tested whether blocking IL-1 signaling in the DH 
would attenuate heroin immunosuppression in order to address whether the effect seen in 
acquisition is due to the interruption of learning and memory or, alternatively, due to blocking 
the immune effects of heroin. Our results suggest that blocking IL-1 signaling in the DH does not 
interfere with acquisition of heroin conditioned immunosuppression by attenuating the 
immunosuppressive effects of heroin, but rather that IL-1 signaling may be specifically involved 
in associative memory formation. However, this conclusion must be tempered with the fact that 
this experiment used a single injection of heroin and a single infusion of IL-1RA. It is unclear 
whether effects would be seen with multiple heroin and/or IL-1RA injections, as used in 
Experiment 1. This possibility will need to be investigated.  
 These results suggest that hippocampal IL-1 signaling is required for the acquisition of 
heroin conditioned immunosuppression, which is in agreement with previous reports 
demonstrating the importance of IL-1 signaling in other hippocampal-dependent forms of 
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memory. However, results from the current study contrast with those of other studies 
investigating conditioned immunosuppression. In particular, Pacheco-López and colleagues 
(2007) showed that intracerebroventricular infusion of IL-1RA had no effect on the acquisition 
of taste-LPS associative memory (Pacheco-Lopez et al., 2007). We propose that this 
incongruence may be due to differences in the neural circuitry involved in the acquisition and 
expression of conditioned taste-immune vs. conditioned opiate-immune effects. It is unclear 
whether conditioned taste effects require the hippocampus in paradigms not employing a 
contextual component (Molero-Chamizo and Moron, 2015). In addition, prior studies 
demonstrated that the amygdala was important for the expression of heroin conditioned 
immunosuppression (Szczytkowski et al., 2011; Szczytkowski and Lysle, 2008, 2010). Immune 
conditioning studies using cyclosporine A paired with a tastant, in contrast, have shown that this 
area was only required during acquisition of conditioned immunosuppression and not during 
expression (Pacheco-Lopez et al., 2005). These differences may be due to the use of different 
unconditioned and conditioned stimuli between taste and opiate conditioned immune effects, 
differential reliance on contextual memory, or differences in experimental design (e.g. targeting 
the basolateral aspect of the amygdala specifically versus the whole amygdalar complex). It was 
also demonstrated that the insular cortex and ventromedial hypothalamus were required 
throughout taste conditioned immmunosuppression or only during expression, respectively 
(Pacheco-Lopez et al., 2005), but it is unknown whether these regions are also required for 
contextual immune conditioning using heroin. Future studies should investigate these potential 
valuable distinctions. 
Though it might be argued that repeated suppression of IL-1 signaling could disrupt 
heroin conditioned immunosuppression through non-specific compensatory mechanisms, the 
disruption of acquisition of this learned effect only when IL-1RA was administered into the DH 
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before conditioning and not on days when conditioning did not take place, argues against this 
notion.  
 From the current results, it is still unclear whether hippocampal IL-1 signaling increases 
during the acquisition phase of heroin conditioned immunosuppression, or whether only basal 
levels are required for heroin context-immune associations to form. There is a plethora of 
experimental evidence that opioids can increase the activation of microglia and astrocytes 
through either glial μ-opioid receptor or toll-like receptor 4 (TLR4) activation, leading to the 
release of proinflammatory cytokines, including IL-1β (Coller and Hutchinson, 2012; 
Hutchinson et al., 2011; Motaghinejad et al., 2015; Wang et al., 2012). However, most of these 
studies were conducted in the spinal cord or under longer-term treatment with opioids than what 
was used in the present studies. Chronic morphine has been shown to elevate astrocyte activation 
in the hippocampus (Song and Zhao, 2001), but again, it is unclear whether this would occur 
following five doses of heroin or whether this would lead to increased release of IL-1β. Stress-
induced IL-1β expression was reduced in the dentate gyrus by morphine (Jones et al., 2015), 
indicating that opioids may have differential effects in different subregions of the hippocampus 
or that opioid action might depend on prior inflammatory states.  
 Neurons might also contribute to the release of IL-1β since both glia and neurons have been 
shown to release IL-1β in the brain (Goshen et al., 2007). TLR4 activation, being upstream of IL-
1β release from glia, might also lead to opioid-mediated release of cytokines from neurons. 
Additionally, if heroin activates microglia in our paradigm, this may lead to potentiated release 
of IL-1β from neurons. Microglial activation following brain injury has been shown to 
upregulate TLR4 expression on hippocampal neurons (Li et al., 2015). Interestingly, this 
neuronal change in TLR4 expression was coupled with increased hippocampal excitability, 
especially in the dentate gyrus, and was increased or decreased by TLR4 agonists or antagonists, 
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respectively. While this effect was not linked to the release of IL-1β directly, there is additional 
evidence indicating that a functional consequence of IL-1β release in the hippocampus could be 
modulation of neuronal excitability. IL-1β has been shown to cause changes in NMDA and 
AMPA receptor dynamics in the hippocampus, inhibit voltage dependent calcium channels in 
CA1, cause permanent inhibition of GABAergic signaling in dentate gyrus and CA3 neurons, 
and yet increase GABAergic signaling in CA1 [see (Schafers and Sorkin, 2008; Vezzani and 
Viviani, 2015)].    
 Also of note is the possibility of CB1-dependent regulation of opioid immune signaling. 
Heroin has been shown to produce CB1 signaling adaptations in the hippocampus following 
acquisition of self-administration (Fattore et al., 2007), indicating that opioids may modulate 
tonic expression of endocannabinoid signaling the hippocampus. There is evidence that basal 
expression of IL-1β in the hippocampus requires cannabinoid receptor, CB1 (Csolle and 
Sperlagh, 2011) therefore, there are multiple ways that opiates might modulate expression of IL-
1β in the hippocampus so that IL-1β can contribute to heroin learning. The functional 
consequence of this IL-1β regulation may be subregion specific changes in neuronal excitability 
in the hippocampus. Future experiments should aim to explore IL-1β expression, glial activation, 
and the neuromodulatory functions of IL-1β in each of the subregions of the hippocampus within 
our heroin conditioning regimen.  
 It must be noted that our manipulation used the IL-1R1 endogenous receptor antagonist, 
IL-1RA. This receptor also binds to IL-1 alpha (IL-1α) and mediates its action, so the specificity 
of IL-1β in mediating the effects seen cannot be concluded definitively. Previous studies have 
shown that IL-1β signaling is required for the expression of heroin conditioned 
immunosuppression to a context through knockdown of IL-1β expression using IL-1β siRNA 
(Szczytkowski et al., 2013). For the current experiment, IL-1β siRNA was not temporally 
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specific enough to target processes only during or shortly after each conditioning session. It has 
been shown in our experience to knockdown expression in vivo for at least 48 hours 
(Szczytkowski et al., 2013), and it has the potential to knockdown gene expression for up to four 
days (Dr. H. Y. Eminy Lee, Personal communication, 2010). IL-1RA, on the other hand, could 
have a much more acute effect, which is why it was used in the present study. Our results seem 
to confirm that the effects of administering IL-1RA 24 hours apart were distinguishable. 
 To our knowledge, despite the fact that a preponderance of evidence suggests that opioid 
use can suppress the immune system in animal models, primates, and humans along with 
concerning evidence that this extends to clinical use, there has been no investigation as to the 
prevalence of opioid conditioned immunosuppression in therapeutic opioid use (Al-Hashimi et 
al., 2013; Brown et al., 2012; Sacerdote, 2006; Sacerdote et al., 2012; Santamaria et al., 2010; 
Vallejo et al., 2004; Wu et al., 2015). Conditioned immunosuppression using other 
immunosuppressive drugs has been demonstrated in humans in the placebo literature (Albring et 
al., 2014; Albring et al., 2012; Goebel et al., 2002), so it is reasonable to hypothesize that opioid 
immune effects would be able to be conditioned in humans as well. This possibility should be 
explored in the future as it has the potential to greatly impact the clinical use of opioids in pain 
and cancer management. The current results suggest that therapeutic inhibition of IL-1 during the 
acquisition phase of associations between the immune system with opioids may help prevent 
usually benign stimuli from suppressing the immune system and may block increased infection 
risk. While more difficult to make use of this treatment in the case of heroin users, IL-1 
inhibition could potentially alleviate immunosuppressive consequences of clinical opioid use. 
Further studies should be conducted to relate the current results to clinical application. The direct 
impact of hippocampal IL-1 blockade on pathogen resistance outcomes should be empirically 
tested. This study provides valuable insight into the neural mechanisms that contribute to heroin 
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conditioned immunosuppression and characterizes IL-1 effects on an important measure of 
conditioned immunity. 
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